المؤلفون: Hoefs, John C, Shiffman, Mitchell L, Goodman, Zachary D, Kleiner, David E, Dienstag, Jules L, Stoddard, Anne M

المصدر: Gastroenterology. 141(3)

مصطلحات موضوعية: Adult, Antiviral Agents: therapeutic use, Biopsy, Carcinoma, Hepatocellular: epidemiology, pathology, Disease Progression, Drug Therapy, Combination, Female, Fibrosis, Hepatitis C, Chronic: diagnosis, drug therapy, pathology, Humans, Interferon-alpha: therapeutic use, Liver: pathology, Liver Cirrhosis: pathology, prevention & control, Liver Neoplasms: epidemiology, pathology, Male, Middle Aged, Polyethylene Glycols: therapeutic use, Prevalence, Prognosis, Recombinant Proteins: therapeutic use, Ribavirin: therapeutic use, Time Factors, Treatment Outcome

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/0f72w504

المؤلفون: Berg, Tobias, Nøttrup, Trine J, Peen, Ulla B S, Roed, Henrik

المصدر: Berg, T, Nøttrup, T J, Peen, U B S & Roed, H 2020, ' Treatment and outcomes of a Danish ovarian cancer population ', Danish Medical Journal, vol. 67, no. 1, A06190346 .

مصطلحات موضوعية: Adult, Ovarian Neoplasms/mortality, Doxorubicin/analogs & derivatives, Denmark, Antineoplastic Agents/therapeutic use, Polyethylene Glycols/therapeutic use, Middle Aged, Neoadjuvant Therapy, Paclitaxel/therapeutic use, Carboplatin/therapeutic use, Treatment Outcome, Disease Progression, Humans, Female, Aged, Neoplasm Staging, Retrospective Studies

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2751::4b8f3dd6c1fcfec6d7b0e1d0f1256c66
https://curis.ku.dk/portal/da/publications/treatment-and-outcomes-of-a-danish-ovarian-cancer-population(acb725ea-8f8e-4a0a-a96c-1885a33e95a9).html

المؤلفون: Zeisig, Eva

مصطلحات موضوعية: Tennis elbow -- drug therapy, Tennis elbow -- therapy, Tennis elbow -- physiopathology, Tennis elbow -- ultrasonography, Tendons -- blood supply, Tendons -- ultrasonography, Anesthetics, local -- therapeutic use, Epinephrine -- therapeutic use, Lidocaine -- therapeutic use, Polyethylene glycols -- therapeutic use, Sclerosing solutions -- therapeutic use, Arthralgia -- therapy

URL الوصول: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1857

Degree: Diss. (sammanfattning) Umeå : Umeå universitet, 2008

المؤلفون: Pedro L Carreira, David A. Isenberg

المصدر: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

مصطلحات موضوعية: HCC DAUTOIM, Interferon-alpha / therapeutic use, Antibodies, Monoclonal, Humanized / therapeutic use, Polyethylene Glycols / therapeutic use, Biological Products / therapeutic use, Bioinformatics, Ofatumumab, Antibodies, Monoclonal, Humanized, Polyethylene Glycols, 03 medical and health sciences, chemistry.chemical_compound, Immunoglobulin Fab Fragments, Lupus Erythematosus, Systemic / drug therapy, 0302 clinical medicine, Immune system, Rheumatology, Obinutuzumab, immune system diseases, medicine, Immunologic Factors, Lupus Erythematosus, Systemic, Humans, Pharmacology (medical), 030212 general & internal medicine, 030203 arthritis & rheumatology, Biological Products, Systemic lupus erythematosus, business.industry, Biologic therapies, Interferon-alpha, Immunoglobulin Fab Fragments / therapeutic use, Rituximab / therapeutic use, medicine.disease, Belimumab, Blockade, Treatment Outcome, chemistry, Rituximab, business, medicine.drug, Immunologic Factors / therapeutic use

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bce569b1664548e4686621bb63698f

المؤلفون: Matthew L. Albert, Yoann Barthe, Armanda Casrouge, Arnaud Fontanet, Stanislas Pol, Sylvie Lagaye, Hélène Fontaine, Vincent Mallet, Philippe Sultanik, Christophe Hézode, Estelle Mottez, Laurent Abel, Etienne Gayat, Céline Dorival, Fabrice Carrat, Jean-Pierre Bronowicki, Ioannis Theodorou

المساهمون: Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hépatologie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunobiologie des Cellules Dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie, systèmes d'information, modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Departement d'Hépatho-Gastro-Enterologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre Hospitalier Universitaire Henri Mondor, Centre d'Immunologie Humaine (CIH), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratory of Human Genetics of Infectious Diseases, Rockefeller University [New York]-Rockefeller Branch, Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of anesthesiology and critical care medicine, Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal, Département Infection et Epidémiologie - Department of Infection and Epidemiology, Institut Pasteur [Paris], The CUPIC Cohort study was sponsored and funded by The National Agency for research on Aids and Viral Hepatitis (ANRS), with support by the French Association for the Study of the Liver(AFEF). The authors also wish to acknowledge the Center for Human Immunology for its support of the research project., Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP), CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Centre Hospitalier Universitaire Henri Mondor, Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR113-Université Pierre et Marie Curie - Paris 6 (UPMC), Rockefeller Branch-rockefeller university, Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Centre Hospitalier Universitaire Henri Mondor, Centre d'Immunologie Humaine ( CIH ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR113-Université Pierre et Marie Curie - Paris 6 ( UPMC ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Biomarqueurs CArdioNeuroVASCulaires ( BioCANVAS ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département Infection et Epidémiologie

المصدر: Liver International
Liver International, Wiley-Blackwell, 2015, 35 (7), pp.1833-1844. ⟨10.1111/liv.12759⟩
Liver International, 2015, 35 (7), pp.1833-1844. ⟨10.1111/liv.12759⟩
Liver International, Wiley-Blackwell, 2015, 35 (7), pp.1833-1844. 〈10.1111/liv.12759〉

مصطلحات موضوعية: Male, MESH : Aged, MESH : Prospective Studies, MESH : Viral Load, MESH : Hepatitis C, Chronic/blood, Hepacivirus, MESH : Virus Replication/drug effects, Polyethylene Glycols, MESH: Molecular Targeted Therapy, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Molecular Targeted Therapy, Prospective Studies, MESH: Ribavirin/therapeutic use, MESH : Proline/analogs & derivatives, MESH: Treatment Outcome, MESH : Hepacivirus/drug effects, MESH: Viral Nonstructural Proteins/metabolism, MESH: Middle Aged, MESH: RNA, Viral/blood, virus diseases, MESH : beta 2-Glycoprotein I/blood, Blood proteins, 3. Good health, beta 2-Glycoprotein I, Area Under Curve, MESH: Hepacivirus/genetics, Drug Therapy, Combination, Oligopeptides, Apolipoprotein H, MESH : Biomarkers/blood, MESH: Hepatitis C, Chronic/drug therapy, Proline, MESH: Hepatitis C, Chronic/blood, virological response, MESH: Proline/analogs & derivatives, MESH : Antiviral Agents/therapeutic use, Antiviral Agents, MESH : Proline/therapeutic use, Boceprevir, MESH : Recombinant Proteins/therapeutic use, Humans, chronic hepatitis C, MESH : Middle Aged, Protease Inhibitors, MESH: Interferon-alpha/therapeutic use, MESH : Predictive Value of Tests, Aged, MESH: Polyethylene Glycols/therapeutic use, MESH : Hepacivirus/genetics, MESH: Humans, Surrogate endpoint, MESH : Humans, MESH: beta 2-Glycoprotein I/blood, MESH: ROC Curve, digestive system diseases, chemistry, MESH: Protease Inhibitors/therapeutic use, Immunology, MESH: Female, Biomarkers, Time Factors, MESH : Viral Nonstructural Proteins/antagonists & inhibitors, MESH : Hepatitis C, Chronic/diagnosis, MESH : Protease Inhibitors/therapeutic use, Viral Nonstructural Proteins, Virus Replication, MESH : Polyethylene Glycols/therapeutic use, HCV protease inhibitor, Telaprevir, MESH: Virus Replication/drug effects, MESH: Proline/therapeutic use, chemistry.chemical_compound, apolipoprotein H, MESH: Hepacivirus/drug effects, MESH : RNA, Viral/blood, MESH : Female, MESH: Hepatitis C, Chronic/diagnosis, MESH : Viral Nonstructural Proteins/metabolism, MESH: Aged, Middle Aged, Viral Load, MESH: Hepacivirus/growth & development, Recombinant Proteins, MESH: Predictive Value of Tests, MESH : Hepacivirus/enzymology, Treatment Outcome, RNA, Viral, biomarker, [SDV.IMM]Life Sciences [q-bio]/Immunology, Biomarker (medicine), Female, France, MESH: Viral Load, MESH : Oligopeptides/therapeutic use, MESH : Time Factors, medicine.drug, MESH : Hepatitis C, Chronic/drug therapy, MESH : Molecular Targeted Therapy, MESH: Biomarkers/blood, MESH: Hepacivirus/enzymology, MESH : Male, MESH : Ribavirin/therapeutic use, MESH : Interferon-alpha/therapeutic use, MESH : Treatment Outcome, Biology, Predictive Value of Tests, MESH: Recombinant Proteins/therapeutic use, Ribavirin, medicine, MESH : France, NS3, MESH: Viral Nonstructural Proteins/antagonists & inhibitors, Hepatology, MESH : Drug Therapy, Combination, MESH: Time Factors, Interferon-alpha, Hepatitis C, Chronic, MESH : Hepacivirus/growth & development, MESH: Male, MESH: Prospective Studies, MESH: France, MESH: Drug Therapy, Combination, ROC Curve, MESH: Antiviral Agents/therapeutic use, MESH: Oligopeptides/therapeutic use, MESH: Area Under Curve, MESH : Area Under Curve, MESH : ROC Curve

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90633f842d8de6ea3f7f4df0ad3c882d
https://doi.org/10.1111/liv.12759

المؤلفون: Dong Zhao, Jingbo Zhao

المصدر: Zhao, D & Zhao, J 2018, ' Comparison of Chang Run Tong and Forlaxin Treatment of Constipation in Elderly Diabetic Patients ' Journal of Alternative & Complementary Medicine, vol. 25, no. 5, pp. 472-480 . https://doi.org/10.1089/acm.2018.0052
Zhao, D & Zhao, J 2018, ' Comparison of Chang Run Tong and Forlaxin Treatment of Constipation in Elderly Diabetic Patients ', Journal of Alternative & Complementary Medicine, vol. 24, no. 5, pp. 472-480 . https://doi.org/10.1089/acm.2018.0052

مصطلحات موضوعية: Male, medicine.medical_specialty, Weakness, China, Constipation, Polyethylene Glycols/therapeutic use, Polyethylene Glycols, Diabetes Complications, 03 medical and health sciences, 0302 clinical medicine, Bloating, Bristol stool scale, Internal medicine, Diabetes mellitus, medicine, Flatulence, Humans, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Drugs, Chinese Herbal/therapeutic use, Aged, business.industry, Constipation/complications, Middle Aged, medicine.disease, Treatment Outcome, Complementary and alternative medicine, 030220 oncology & carcinogenesis, Defecation, Female, medicine.symptom, business, Drugs, Chinese Herbal

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db43d326f24d26df2802a6a81d850f1b
https://pure.au.dk/portal/da/publications/comparison-of-chang-run-tong-and-forlaxin-treatment-of-constipation-in-elderly-diabetic-patients(66edc38f-838a-4df6-89ee-a417fd3f64e2).html

المؤلفون: Colin A. Semple, Tzyvia Rye, Michael Churchman, Alison M. Meynert, Mark J. Arends, Andrew H. Sims, Robert L Hollis, Fiona Nussey, Melanie Mackean, Charlie Gourley, C. Simon Herrington

المصدر: BMC Cancer
Hollis, R L, Meynert, A M, Churchman, M, Rye, T, Mackean, M, Nussey, F, Arends, M J, Sims, A H, Semple, C A, Herrington, C S & Gourley, C 2018, ' Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations ', BMC Cancer, vol. 18, no. 1, pp. 16 . https://doi.org/10.1186/s12885-017-3981-2
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, endocrine system diseases, medicine.medical_treatment, Polyethylene Glycols, 0302 clinical medicine, Surgical oncology, Ovarian carcinoma, Medicine, skin and connective tissue diseases, Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, Antibiotics, Antineoplastic, Cystadenocarcinoma, Serous/drug therapy, BRCA1 Protein, Ovarian Neoplasms/drug therapy, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, BRCA2 Protein/genetics, 3. Good health, Survival Rate, Serous fluid, Antibiotics, Antineoplastic/therapeutic use, 030220 oncology & carcinogenesis, Female, Biomarkers, Tumor/genetics, Research Article, Adult, Doxorubicin/analogs & derivatives, medicine.medical_specialty, DNA repair, Population, Polyethylene Glycols/therapeutic use, lcsh:RC254-282, Polymorphism, Single Nucleotide, 03 medical and health sciences, Ovarian cancer, Internal medicine, Biomarkers, Tumor, Genetics, Humans, Genetic Predisposition to Disease, education, Survival rate, Aged, Retrospective Studies, BRCA2 Protein, Chemotherapy, business.industry, BRCA1, medicine.disease, BRCA2, Cystadenocarcinoma, Serous, 030104 developmental biology, Doxorubicin, Mutation, BRCA1 Protein/genetics, Neoplasm Grading, business, PLDH, Follow-Up Studies

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96400cfe4b9d479a18a0495e22787eaa
https://doi.org/10.1186/s12885-017-3981-2

المؤلفون: Laurent Alric, Frederic Davi, Juliette Jeannel, Stanislas Pol, Delphine Bonnet, Nathanael Lapidus, Jean-Marie Michot, Olivier Hermine, Danielle Canioni, Loic Ysebaert, Pascaline Rabiega, Patrice Cacoub, Caroline Besson

المساهمون: Institut de Recherche en Santé Digestive (IRSD ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de pathologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service d'hépatologie médicale [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'immuno-hématologie pédiatrique [CHU Necker], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence Nationale de Recherche sur le Sida et les Hépatites (ANRS), France Recherche Nord Sud Sida-HIV Hépatite, HAL UPMC, Gestionnaire, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut de Recherche en Santé Digestive - IRSD [Purpan, Toulouse], Institut National de la Recherche Agronomique ( INRA ) -Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse ( ENVT ), Institut National Polytechnique de Toulouse ( INPT ) -Institut National Polytechnique de Toulouse ( INPT ) -Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Immunologie des Maladies Virales et Autoimmunes ( IMVA - U1184 ), Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Institut Universitaire du Cancer de Toulouse - Oncopole ( IUCT Oncopole - UMR 1037 ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale ( INSERM )

المصدر: PLoS ONE
PLoS ONE, Public Library of Science, 2016, 11 (10), pp.e0162965. ⟨10.1371/journal.pone.0162965⟩
PLoS ONE, 2016, 11 (10), pp.e0162965. ⟨10.1371/journal.pone.0162965⟩
PLoS ONE, Vol 11, Iss 10, p e0162965 (2016)
PLoS ONE, Public Library of Science, 2016, 11 (10), pp.e0162965. 〈10.1371/journal.pone.0162965〉

مصطلحات موضوعية: Male, Interferon-alpha / therapeutic use, Hepacivirus, Gastroenterology, Polyethylene Glycols, Hematologic Cancers and Related Disorders, 0302 clinical medicine, B-Cell Marginal Zone / complications, Odds Ratio, Public and Occupational Health, lcsh:Science, Non-Hodgkin lymphoma, Hazard ratio, virus diseases, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, B-Cell Non-Hodgkin Lymphoma, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Hepacivirus / genetics, Clinical Oncology, medicine.medical_specialty, Lymphoma, B-Cell, Genotype, Ribavirin / therapeutic use, Immunology, Hepatitis C / mortality, Antiviral Agents, Microbiology, 03 medical and health sciences, Pharmacotherapy, Drug Therapy, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, B-Cell / diagnosis, Humans, Protease Inhibitors, Aged, Flaviviruses, lcsh:R, Organisms, Biology and Life Sciences, Odds ratio, medicine.disease, digestive system diseases, Lymphoma, chemistry, Hepatitis C / virology, Protease Inhibitors / therapeutic use, lcsh:Q, Preventive Medicine, Clinical Medicine, Hepatitis C / drug therapy, RNA viruses, Viral / metabolism, Cancer Treatment, lcsh:Medicine, medicine.disease_cause, chemistry.chemical_compound, immune system diseases, hemic and lymphatic diseases, Medicine and Health Sciences, Pathology and laboratory medicine, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Multidisciplinary, Protease Inhibitor Therapy, Hepatitis C virus, Pharmaceutics, Hepatitis C / complications, Hematology, Medical microbiology, Middle Aged, Hepatitis C, Vaccination and Immunization, Viral / blood, Recombinant Proteins, Treatment Outcome, Research Design, Viruses, Combination, RNA, Viral, Lymphomas, Female, Lymphoma, Large B-Cell, Diffuse, Pathogens, Research Article, Clinical Research Design, Polyethylene Glycols / therapeutic use, Antiviral Agents / therapeutic use, Antiretroviral Therapy, Enzyme-Linked Immunosorbent Assay, Research and Analysis Methods, B-Cell / complications, Antiviral Therapy, Large B-Cell Diffuse / complications, Internal medicine, Ribavirin, medicine, Chemotherapy, Survival rate, Hepacivirus / isolation & purification, Proportional Hazards Models, Recombinant Proteins / therapeutic use, business.industry, Viral pathogens, Interferon-alpha, Cancers and Neoplasms, Lymphoma, B-Cell, Marginal Zone, Hepatitis viruses, Microbial pathogens, Multivariate Analysis, RNA, Adverse Events, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7457032023c21fa2ecbe6c98da1691b5
https://hal.sorbonne-universite.fr/hal-01408993/document

المؤلفون: Bente Mertz Nørgård, Jens Kjeldsen, Niels Qvist, Kim Oren Gradel, Jan Nielsen, O B Schaffalitzky de Muckadell

المصدر: Nørgård, B M, Nielsen, J, Qvist, N, Gradel, K O, Schaffalitzky de Muckadell, O B & Kjeldsen, J 2013, ' Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease-A nationwide cohort study ', Alimentary Pharmacology and Therapeutics, vol. 37, no. 2, pp. 214-224 . https://doi.org/10.1111/apt.12159

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Time Factors, Adolescent, Denmark, Anti-Inflammatory Agents, Anastomosis, Antibodies, Monoclonal, Humanized, Preoperative care, Polyethylene Glycols, Cohort Studies, Immunoglobulin Fab Fragments, Young Adult, Postoperative Complications, Crohn Disease, Adolescent Adult Aged Aged, 80 and over Anti-Inflammatory Agents/therapeutic use Antibodies, Monoclonal/therapeutic use *Antibodies, Monoclonal, Humanized/therapeutic use Cohort Studies Crohn Disease/drug therapy/*surgery Denmark Female Humans Immunoglobulin Fab Fragments/therapeutic use Logistic Models Male Middle Aged Polyethylene Glycols/therapeutic use *Postoperative Complications Preoperative Care Risk Factors Time Factors Tumor Necrosis Factor-alpha/*antagonists & inhibitors Young Adult, Risk Factors, Preoperative Care, medicine, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Crohn's disease, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Adalimumab, Gastroenterology, Antibodies, Monoclonal, Odds ratio, Middle Aged, medicine.disease, Infliximab, Surgery, Logistic Models, Relative risk, Cohort, Certolizumab Pegol, Female, business, Cohort study, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ee27e3f1f0b4a24c01d429f2b5aa4e4
https://doi.org/10.1111/apt.12159

المؤلفون: Vicente Ruiz Garcia, Paresh Jobanputra, Amanda Burls, Juan B Cabello, Paloma Vela Casasempere, Sylvia Bort-Marti, Francis JB Kynaston-Pearson

المصدر: The Cochrane Database of Systematic Reviews
The Cochrane Library
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

مصطلحات موضوعية: Medicine General & Introductory Medical Sciences, Adult, medicine.medical_specialty, Immunoglobulin Fab Fragments [therapeutic use], Antirheumatic Agents [therapeutic use], Cochrane Library, Antibodies, Monoclonal, Humanized, Placebo, Polyethylene Glycols, Arthritis, Rheumatoid, Immunoglobulin Fab Fragments, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Certolizumab pegol, Adverse effect, Randomized Controlled Trials as Topic, 030203 arthritis & rheumatology, business.industry, Odds ratio, Surgery, Methotrexate, Withholding Treatment, Antirheumatic Agents, Meta-analysis, Relative risk, Certolizumab Pegol, Number needed to treat, Arthritis, Rheumatoid [drug therapy], Polyethylene Glycols [therapeutic use], business, medicine.drug, RC

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eedae4ff68f0cdc8415b09bee9cc824a
https://doi.org/10.1002/14651858.cd007649.pub3